N
Neurogene
Biotech & Life Sciences · New York City, United States · Founded 2018 · IPO 2023
Focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases MoreLess
Neurogene is a biotechnology company dedicated to developing genetic medicines aimed at treating rare and devastating neurological diseases. The company focuses on creating life-changing therapies for patients and their families who are affected by these conditions. Neurogene operates in the healthcare and biotechnology market, primarily serving patients with rare neurological disorders, a segment that often lacks effective treatment options.
The business model of Neurogene revolves around research and development (R&D) of gene therapy candidates. The company invests heavily in scientific research to identify and develop potential treatments, which are then tested through clinical trials. Revenue is generated through partnerships, grants, and potentially through the commercialization of successful therapies.
Neurogene's headquarters are located in New York, with a manufacturing facility in Houston, Texas. The company is led by a senior leadership team with extensive experience in drug development and a strong commitment to their mission.
Keywords: genetic medicines, rare diseases, neurological disorders, biotechnology, gene therapy, clinical trials, healthcare, R&D, drug development, life-changing therapies.
Company overview
Neurogene company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- New York City, United States
- Employees
- 136
- Open positions
- 15
- Dealroom signal
- 91.5
- Investment activity
- 1 companies · latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Neurogene funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $0 | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Nov 2024 | $200M | — | Casdin Capital · EcoR1 Capital · Great Point Partners · Redmile Group | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2023 | $95M | — | BlackRock · Redmile Group · Samsara BioCapital · Avidity Partners | ↗ |
| IPOOther financing | Jul 2023 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Dec 2020 | $115M | $460M | Casdin Capital · Ascendant Capital · Samsara BioCapital · BlackRock | — |
| SERIES AOther financing | Feb 2019 | Redmile Group · EcoR1 Capital · Cormorant Asset Management · Samsara BioCapital | — | ||
| SPINOUTOther financing | Jan 2018 | University of Washington | — |
Growth signals
Neurogene website traffic
Latest recorded traffic for Neurogene is 7.6K monthly website visits, down 7.3% over the last three months. Neurogene's team grew 20.4% over the past year.
Hiring
Open positions at Neurogene
Current openings linked to this company in Dealroom.
Comparisons
Neurogene compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Neurogene investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Neurogene's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Neurogene has talent and traffic
In the news
Latest news about Neurogene
Recent press, funding announcements, and product moves mentioning Neurogene — open to read from the original sources.
Market sentiment
What the market is saying about Neurogene
An AI-synthesized read of the highest-engagement posts about Neurogene on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurogene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.